Evidence map›Paper›PMID 32846935›Full record

ArticleJournal of clinical medicine2020

SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease.

Swetha R Kanduri, Karthik Kovvuru, Panupong Hansrivijit, Charat Thongprayoon, Saraschandra Vallabhajosyula, Aleksandra I Pivovarova, Api Chewcharat, Vishnu Garla, Juan Medaura, Wisit Cheungpasitporn

Open access · goldAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 4 pooled it
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Advances in understanding the innate immune-associated diabetic kidney disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021
    Review
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Swetha R KanduriDepartment of Nephrology, Ochsner Medical Center, New Orleans, LA 70121, USA.ORCID 0000-0002-7190-6665
Karthik KovvuruDepartment of Nephrology, Ochsner Medical Center, New Orleans, LA 70121, USA.
Panupong HansrivijitDepartment of Internal Medicine, University of Pittsburgh Medical Center Pinnacle, Harrisburg, PA 17105, USA.ORCID 0000-0002-5041-4290
Charat ThongprayoonDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA.
Saraschandra VallabhajosyulaSection of Interventional Cardiology, Division of Cardiovascular Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Aleksandra I PivovarovaDivision of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39156, USA.ORCID 0000-0002-1335-7696
Api ChewcharatDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA.
Vishnu GarlaDepartment of Internal Medicine and Mississippi Center for Clinical and Translational Research, University of Mississippi Medical Center, Jackson, MS 39156, USA.
Juan MedauraDivision of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39156, USA.
Wisit CheungpasitpornDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-9954-9711
Mayo Clinic · USUniversity of Mississippi Medical Center · USOchsner Medical Center · USEmory University · USUPMC Central Pa · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Globally, diabetes mellitus is a leading cause of kidney disease, with a critical percent of patients approaching end-stage kidney disease. In the current era, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as phenomenal agents in halting the progression of kidney disease. Positive effects of SGLT2i are centered on multiple mechanisms, including glycosuric effects, tubule-glomerular feedback, antioxidant, anti-fibrotic, natriuretic, and reduction in cortical hypoxia, alteration in energy metabolism. Concurrently, multiple kidney and cardiovascular outcome studies have reported remarkable advantages of SGLT2i including mortality benefits. Additionally, the superiority of combination therapies (SGLT2I along with metformin/DDP-4 Inhibitors) in treatment-naïve diabetic patients is further looked into with potential signal towards glycemic and blood pressure control. Reported promising results initiate a gateway for future research targeting kidney outcomes with combination therapies as an initial approach. In the current paper, we summarize leading cardiovascular and kidney outcome trials in patients with type 2 diabetes, the role of SGLT2i in non-diabetic proteinuric kidney disease, and the potential mechanisms of action of SGLT2i with special focus on combination therapy as an initial therapeutic approach in treatment-naïve diabetic patients.

Indexed as

cardiologyDiabetes mellitusendocrinologynephrologySGLT2SGLT2isodium glucose co-transporter 2 inhibitors

Identifiers

PMID32846935
PMCPMC7564486
OpenAlexW3080518304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.